What are the FDA‑approved indications and recommended dosing for upadacitinib (Rinvoq) in adults and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FDA-Approved Indications of Upadacitinib (Rinvoq)

Upadacitinib is FDA-approved for multiple immune-mediated inflammatory conditions in both adults and children, with specific dosing that varies by indication and patient age. 1

FDA-Approved Indications in Adults

Rheumatologic Conditions

  • Rheumatoid Arthritis: For adults with moderately to severely active disease who have had inadequate response or intolerance to methotrexate 1

    • Dosing: 15 mg once daily 1
  • Psoriatic Arthritis: For adults with active disease who have had inadequate response or intolerance to one or more TNF blockers 1

    • Dosing: 15 mg once daily 1
  • Ankylosing Spondylitis: For adults with active disease who have had inadequate response or intolerance to one or more TNF blockers 1

    • Dosing: 15 mg once daily 1
  • Non-radiographic Axial Spondyloarthritis: For adults with active disease with objective signs of inflammation who have had inadequate response or intolerance to TNF blocker therapy 1

    • Dosing: 15 mg once daily 1

Dermatologic Conditions

  • Atopic Dermatitis: For adults and adolescents ≥12 years with moderate-to-severe disease who have failed other systemic therapies (immunosuppressants, corticosteroids, antimetabolites, injectable biologics) or when they are inadvisable 2, 1
    • Adults <65 years: Initiate with 15 mg once daily; may increase to 30 mg once daily if inadequate response 1
    • Adults ≥65 years: 15 mg once daily only 1
    • Adolescents ≥12 years weighing ≥40 kg: Same as adults <65 years 1
    • The 30 mg dose demonstrates the highest efficacy among all available AD treatments and is superior to dupilumab in head-to-head trials 2

Gastrointestinal Conditions

  • Ulcerative Colitis: For adults with moderately to severely active disease who have had inadequate response or intolerance to one or more TNF blockers 3, 1

    • Induction: 45 mg once daily for 8 weeks 1
    • Maintenance: 15 mg once daily; may consider 30 mg once daily for refractory, severe, or extensive disease 1
  • Crohn's Disease: For adults with moderately to severely active disease who have had inadequate response or intolerance to one or more TNF blockers 1

    • Induction: 45 mg once daily for 12 weeks 1
    • Maintenance: 15 mg once daily; may consider 30 mg once daily for refractory, severe, or extensive disease 1

FDA-Approved Indications in Pediatric Patients

Rheumatologic Conditions in Children

  • Polyarticular Juvenile Idiopathic Arthritis: For patients ≥2 years with active disease who have had inadequate response or intolerance to one or more TNF blockers 1, 4

    • Weight-tiered dosing: Based on body weight using either extended-release tablets (once daily) or oral solution (twice daily) 1, 4
  • Psoriatic Arthritis: For patients ≥2 years weighing ≥10 kg with active disease who have had inadequate response or intolerance to one or more TNF blockers 1, 4

    • Weight-tiered dosing: Based on body weight 1

Critical Positioning and Limitations of Use

Upadacitinib is NOT first-line therapy for most indications 2

  • For atopic dermatitis: Reserved for patients who have failed conventional systemic treatments 2
  • For rheumatologic and GI conditions: Reserved for TNF blocker failures or intolerance 1
  • JAK inhibitors have restricted use in advanced therapy-naïve patients per FDA labeling 3

Contraindicated Combinations

Do not use upadacitinib with: 1

  • Other JAK inhibitors
  • Biologic immunomodulators or biologic DMARDs
  • Potent immunosuppressants (azathioprine, cyclosporine)

Dose Modifications for Special Populations

Renal Impairment

  • Severe renal impairment (CrCl <30 mL/min): Maximum dose 15 mg once daily 1

Hepatic Impairment

  • Severe hepatic impairment (Child-Pugh C): Contraindicated 1

Pre-Treatment Requirements

Before initiating upadacitinib, complete the following: 2, 5

  • Test for latent tuberculosis and treat if positive
  • Administer all needed live vaccines (particularly herpes zoster vaccine for older patients)
  • Baseline laboratory testing: CBC with differential, liver enzymes, lipid profile
  • Test for viral hepatitis B and C
  • Pregnancy testing in women of reproductive potential

Laboratory Monitoring Schedule

  • Baseline: CBC with differential, liver enzymes, renal function, lipids 2
  • After initiation: Lipids at 12 weeks 2
  • Ongoing: Per routine management 2

Black Box Warnings and Safety Considerations

The FDA has applied class-wide warnings for all JAK inhibitors based on data from tofacitinib in rheumatoid arthritis patients ≥50 years with cardiovascular risk factors: 2, 5

  • Increased risk of major adverse cardiovascular events
  • Increased risk of malignancies
  • Increased risk of venous thromboembolism
  • Increased risk of death

Exercise particular caution in patients ≥50 years with cardiovascular risk factors (current/previous smoking, history of cardiovascular disease, history of cancer) 5, 6

Patients ≥65 years with cardiovascular risk factors should avoid upadacitinib unless no alternatives exist 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.